Business
Sonoma Pharmaceuticals Reports First Quarter 2022 Financial Results
Revenues up $1.5 million, or 71%, compared to prior quarter ended March 31, 2021, down $2.1 million, or 36%, as compared to $5.8 million in quarter ended
About this update from Sonoma Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nRevenues up $1.5 million, or 71%, compared to prior quarter ended March 31, 2021, down $2.1 million, or 36%, as compared to $5.8 million in quarter ended June 30, 2020\n\n\nReduced expenses as a result of transition of U.S. prescription dermatology and eye care sales to EMC Pharma \n\n\nNet Loss of $1.1 million, down $2.5 million from prior quarter ended March 31, 2021, and EBITDAS loss of $0.8 million, down $1.9 million from prior quarter\n\n\nNet Loss per share of $0.52 per share, down $1.24, compared to a net loss of $1.76 per share for the quarter ended March 31, 2021\n\n\n \n\n WOODSTOCK, Ga.--(BUSINESS WIRE)--\nSonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and, nasal care, disinfectant use and dermatological conditions today announced financial results for its first fiscal quarter ended June 30, 2021.\n\n“This quarter marks the transition from having a dedicated dermatology sales force for our prescription products to a distribution model,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. She continued, “We had some remaining expenses related to the transition in the first quarter, however, we remain confident that this transaction was critical to the Company’s success by transitioning our prescription business to a model where we believe it can contribute profitably to our overall business. As we complete the transition of the sales portion of the prescription business to EMC, we expect to shift our focus to our growing, successful core business.”\n\nBusiness Highlights\n\nSonoma continues to increase the reach of its products through its own efforts as well as through its partners’ efforts:\n\n\nSonoma’s Australian partner, Microsafe Care Group, added a significant new customer when Nanocyn® was accepted to help fight COVID-19 in Australia as a surface disinfectant by the Royal Flying Doctor Service in their fleet of aircraft. The RFDS has been servicing Australia for 92 years providing vital emergency medical and primary healthcare services for regional, rural, and remote Australians. See http://www.flyingdoctor.org.au/qld/news/rfds-sources-new-decontaminant-battle-against-covid-19/ for more information.\n\n\n\nIn the United Kingdom, MicrocynAH® is now avai...